We further examined if simultaneous administration of a clinically approved anti-resorptive, alendronate, could mitigate loss-of-bone mass and extend the beneficial anti-tumor effects of PORCN inhibitors to a larger number of human patients. This evidence concerns the gene PORCN and neoplasm.